Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SkyePharma executes patient recruitment in Flutiform Phase III trials
Flutiform HFA-MDI is said to be a fixed-dose combination of fluticasone and formoterol in a metered dose inhaler (MDI). SkyePharma said that the two Phase III trials will
Flutiform HFA-MDI is said to be a fixed-dose combination of fluticasone and formoterol in a metered dose inhaler (MDI). SkyePharma said that the two Phase III trials will
Tekmira Pharma said that the EPO has granted claims (European patent no 1 519 714 B1) covering Tekmira’s proprietary manufacturing process and apparatus for the production of lipid
The FDA will review the protocol under its Special Protocol Assessment (SPA) program, under which it will give approval for the trial’s design, clinical endpoints and statistical analysis.
Grifols said that approval from the US Food and Drug Administration (FDA) for Flebogamma 10% DIF was obtained in July 2010 and final approval in Europe is expected
With the manufacturing license granted, Hebei Aoxing API Pharmaceucitcal Company submitted business license application, to manufacture Naloxone Hydrochloride API product, to the China Administrative Bureau of Industry and
Cymbalta is marketed by Eli Lilly and Company. Cymbalta is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder, generalised anxiety disorder, diabetic
Abbott‘s Atrasentan Phase 2 study was a double-blind, dose-ranging, placebo-controlled study of subjects with diabetic nephropathy on stable doses of renin-angiotensin system (RAS) inhibitors for more than 2
Par Pharma began shipping 10mg and 20mg strengths of Zafirlukast tablets on 19 November 2010. Accolate, an oral prescription medicine used to treat asthma, works by blocking substances
Azixa is a novel small molecule that acts as a microtubule destabilising agent, causing an arrest of cell division with subsequent programmed cell death, or apoptosis, in cancer
The PTR-35 is designed for vertical mixing applications including hybridisation reactions, cell growing, homogenisation of biological solutions, prevention of blood coagulation and latex diagnostics. The rotator which is